Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality.


Journal

medRxiv : the preprint server for health sciences
Titre abrégé: medRxiv
Pays: United States
ID NLM: 101767986

Informations de publication

Date de publication:
12 Mar 2021
Historique:
entrez: 24 3 2021
pubmed: 25 3 2021
medline: 25 3 2021
Statut: epublish

Résumé

There is considerable variability in COVID-19 outcomes amongst younger adults-and some of this variation may be due to genetic predisposition. We characterized the clinical implications of the major genetic risk factor for COVID-19 severity, and its age-dependent effect, using individual-level data in a large international multi-centre consortium. The major common COVID-19 genetic risk factor is a chromosome 3 locus, tagged by the marker rs10490770. We combined individual level data for 13,424 COVID-19 positive patients (N=6,689 hospitalized) from 17 cohorts in nine countries to assess the association of this genetic marker with mortality, COVID-19-related complications and laboratory values. We next examined if the magnitude of these associations varied by age and were independent from known clinical COVID-19 risk factors. We found that rs10490770 risk allele carriers experienced an increased risk of all-cause mortality (hazard ratio [HR] 1·4, 95% confidence interval [CI] 1·2-1·6) and COVID-19 related mortality (HR 1·5, 95%CI 1·3-1·8). Risk allele carriers had increased odds of several COVID-19 complications: severe respiratory failure (odds ratio [OR] 2·0, 95%CI 1·6-2·6), venous thromboembolism (OR 1·7, 95%CI 1·2-2·4), and hepatic injury (OR 1·6, 95%CI 1·2-2·0). Risk allele carriers ≤ 60 years had higher odds of death or severe respiratory failure (OR 2·6, 95%CI 1·8-3·9) compared to those > 60 years OR 1·5 (95%CI 1·3-1·9, interaction p-value=0·04). Amongst individuals ≤ 60 years who died or experienced severe respiratory COVID-19 outcome, we found that 31·8% (95%CI 27·6-36·2) were risk variant carriers, compared to 13·9% (95%CI 12·6-15·2%) of those not experiencing these outcomes. Prediction of death or severe respiratory failure among those ≤ 60 years improved when including the risk allele (AUC 0·82 vs 0·84, p=0·016) and the prediction ability of rs10490770 risk allele was similar to, or better than, most established clinical risk factors. The major common COVID-19 risk locus on chromosome 3 is associated with increased risks of morbidity and mortality-and these are more pronounced amongst individuals ≤ 60 years. The effect on COVID-19 severity was similar to, or larger than most established risk factors, suggesting potential implications for clinical risk management. Funding was obtained by each of the participating cohorts individually.

Sections du résumé

BACKGROUND BACKGROUND
There is considerable variability in COVID-19 outcomes amongst younger adults-and some of this variation may be due to genetic predisposition. We characterized the clinical implications of the major genetic risk factor for COVID-19 severity, and its age-dependent effect, using individual-level data in a large international multi-centre consortium.
METHOD METHODS
The major common COVID-19 genetic risk factor is a chromosome 3 locus, tagged by the marker rs10490770. We combined individual level data for 13,424 COVID-19 positive patients (N=6,689 hospitalized) from 17 cohorts in nine countries to assess the association of this genetic marker with mortality, COVID-19-related complications and laboratory values. We next examined if the magnitude of these associations varied by age and were independent from known clinical COVID-19 risk factors.
FINDINGS RESULTS
We found that rs10490770 risk allele carriers experienced an increased risk of all-cause mortality (hazard ratio [HR] 1·4, 95% confidence interval [CI] 1·2-1·6) and COVID-19 related mortality (HR 1·5, 95%CI 1·3-1·8). Risk allele carriers had increased odds of several COVID-19 complications: severe respiratory failure (odds ratio [OR] 2·0, 95%CI 1·6-2·6), venous thromboembolism (OR 1·7, 95%CI 1·2-2·4), and hepatic injury (OR 1·6, 95%CI 1·2-2·0). Risk allele carriers ≤ 60 years had higher odds of death or severe respiratory failure (OR 2·6, 95%CI 1·8-3·9) compared to those > 60 years OR 1·5 (95%CI 1·3-1·9, interaction p-value=0·04). Amongst individuals ≤ 60 years who died or experienced severe respiratory COVID-19 outcome, we found that 31·8% (95%CI 27·6-36·2) were risk variant carriers, compared to 13·9% (95%CI 12·6-15·2%) of those not experiencing these outcomes. Prediction of death or severe respiratory failure among those ≤ 60 years improved when including the risk allele (AUC 0·82 vs 0·84, p=0·016) and the prediction ability of rs10490770 risk allele was similar to, or better than, most established clinical risk factors.
INTERPRETATION CONCLUSIONS
The major common COVID-19 risk locus on chromosome 3 is associated with increased risks of morbidity and mortality-and these are more pronounced amongst individuals ≤ 60 years. The effect on COVID-19 severity was similar to, or larger than most established risk factors, suggesting potential implications for clinical risk management.
FUNDING BACKGROUND
Funding was obtained by each of the participating cohorts individually.

Identifiants

pubmed: 33758887
doi: 10.1101/2021.03.07.21252875
pmc: PMC7987046
pii:
doi:

Types de publication

Preprint

Langues

eng

Subventions

Organisme : NCATS NIH HHS
ID : UL1 TR001873
Pays : United States

Commentaires et corrections

Type : UpdateIn

Références

Eur Heart J. 2013 Dec;34(45):3478-90a
pubmed: 23956253
Nature. 2021 Feb;590(7844):140-145
pubmed: 33137809
Liver Res. 2021 Mar;5(1):21-27
pubmed: 33520337
Nat Commun. 2020 Nov 12;11(1):5749
pubmed: 33184277
Breast Cancer Res Treat. 2010 Dec;124(3):643-51
pubmed: 20204502
Nature. 2015 Oct 1;526(7571):68-74
pubmed: 26432245
Nat Biotechnol. 2020 Aug;38(8):970-979
pubmed: 32591762
Nat Med. 2020 Oct;26(10):1636-1643
pubmed: 32839624
N Engl J Med. 2020 Oct 15;383(16):1522-1534
pubmed: 32558485
Int J Public Health. 2020 Nov;65(8):1435-1436
pubmed: 32978645
EClinicalMedicine. 2020 Aug;25:100464
pubmed: 32838237
Nat Med. 2020 Jun;26(6):842-844
pubmed: 32398875
PLoS Med. 2020 Sep 22;17(9):e1003346
pubmed: 32960881
Nature. 2010 Sep 2;467(7311):52-8
pubmed: 20811451
Nature. 2020 May;581(7809):434-443
pubmed: 32461654
Comput Struct Biotechnol J. 2021;19:976-988
pubmed: 33558827
Nat Med. 2020 May;26(5):640-642
pubmed: 32273610
Am J Emerg Med. 2021 Feb;40:11-14
pubmed: 33333477
Nature. 2020 Nov;587(7835):610-612
pubmed: 32998156
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Nat Rev Rheumatol. 2020 Oct;16(10):581-589
pubmed: 32733003
Am J Epidemiol. 2017 Nov 1;186(9):1026-1034
pubmed: 28641372
Eur J Hum Genet. 2020 Jun;28(6):715-718
pubmed: 32404885
Signal Transduct Target Ther. 2021 Feb 22;6(1):85
pubmed: 33619245
MMWR Morb Mortal Wkly Rep. 2021 Jan 01;69(5152):1657-1660
pubmed: 33382671
N Engl J Med. 2020 Dec 31;383(27):2684-2686
pubmed: 33326716
Amino Acids. 2015 Apr;47(4):693-705
pubmed: 25534429
Am J Hum Genet. 2007 Sep;81(3):559-75
pubmed: 17701901

Auteurs

Tomoko Nakanishi (T)

Institute for Molecular Medicine Finland, Univerisity of Helsinki, Helsinki, Finland.
Department of Human Genetics, McGill University, Montréal, Québec, Canada.
Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, Québec, Canada.
Kyoto-McGill International Collaborative School in Genomic Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Research Fellow, Japan Society for the Promotion of Science, Tokyo, Japan.

Sara Pigazzini (S)

Institute for Molecular Medicine Finland, Univerisity of Helsinki, Helsinki, Finland.
University of Milano-Bicocca, Milano, Italy.

Frauke Degenhardt (F)

Institute of Clinical Molecular Biology, Christian-Albrechts-University, Kiel, Germany.
University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.

Mattia Cordioli (M)

Institute for Molecular Medicine Finland, Univerisity of Helsinki, Helsinki, Finland.

Guillaume Butler-Laporte (G)

Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, Québec, Canada.
Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montréal, Québec, Canada.

Douglas Maya-Miles (D)

Digestive Diseases Unit, Virgen del Rocio University Hospital, Institute of Biomedicine of Seville, University of Seville, Seville, Spain.
Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.

Beatriz Nafría-Jiménez (B)

Osakidetza Basque Health Service, Donostialdea Integrated Health Organisation. Clinical Biochemistry Department, Sebastian, Spain.

Youssef Bouysran (Y)

Centre de Génétique Humaine, Hopital Erasme, Université Libre de Bruxelles, Brussels, Belgium.

Mari Niemi (M)

Institute for Molecular Medicine Finland, Univerisity of Helsinki, Helsinki, Finland.

Adriana Palom (A)

Liver Unit, Department of Internal Medicine, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Universitat Autònoma de Barcelona. Departament de Medicina.Bellatera, Barcelona, Spain.
Vall d'Hebron Institut de Recerca (VHIR). Liver Diseases.

David Ellinghaus (D)

Institute of Clinical Molecular Biology, Christian-Albrechts-University, Kiel, Germany.
Novo Nordisk Foundation Center for Protein Research, Disease Systems Biology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen.

Atlas Khan (A)

Division of Nephrology, Department of Medicine, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY.

Manuel Martínez-Bueno (M)

GENYO. Centre for Genomics and Oncological Research: Pfizer / University of Granada / Andalusian Regional Government, Granada, Spain.

Selina Rolker (S)

Institute of Human Genetics, University Hospital Bonn, Medical Faculty University of Bonn, Bonn, Germany.

Sara Amitano (S)

Genetica Medica, Azienda Ospedaliero-Universitaria Senese, Italy.

Luisa Roade Tato (LR)

Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
Liver Unit, Department of Internal Medicine, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Universitat Autònoma de Barcelona. Departament de Medicina.Bellatera, Barcelona, Spain.

Francesca Fava (F)

Genetica Medica, Azienda Ospedaliero-Universitaria Senese, Italy.
Medical Genetics, University of Siena, Italy.
Med Biotech Hub and Competence Center, Department of Medical Biotechnologies, University of Siena, Italy.

Christoph D Spinner (CD)

Technical University of Munich, School of Medicine, University Hospital rechts der Isar, Department of Internal Medicine II, Munich, Germany.

Daniele Prati (D)

Department of Transfusion Medicine and Hematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milano, Italy.

David Bernardo (D)

Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
Mucosal Immunology Lab, Institute of Biomedicine and Molecular Genetics (IBGM), University of Valladolid-CSIC. Valladolid, Spain.

Federico Garcia (F)

Hospital Universitario Clinico San Cecilio, Granada, Spain.
Instituto de Investigación Ibs.Granada. Granada, Spain.

Gilles Darcis (G)

University of Liege, GIGA-Insitute, Liege, Belgium.
Liege University Hospital (CHU of Liege), Liege, Belgium.

Israel Fernández-Cadenas (I)

Stroke Pharmacogenomics and Genetics Group, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain.

Jan Cato Holter (JC)

Department of Microbiology, Oslo University Hospital, Oslo, Norway.
Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Jesus Banales (J)

Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute - Donostia University Hospital, University of the Basque Country (UPV/EHU), CIBERehd, Ikerbasque, San Sebastian, Spain.

Robert Frithiof (R)

Department of Surgical Sciences, Anaesthesiology and Intensive Care Medicine, Uppsala University, Uppsala, Sweden.

Krzysztof Kiryluk (K)

Division of Nephrology, Department of Medicine, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY.

Stefano Duga (S)

Department of Biomedical Sciences, Humanitas University, Milan, Italy.
IRCCS Humanitas Research Hospital, Milan, Italy.

Rosanna Asselta (R)

Department of Biomedical Sciences, Humanitas University, Milan, Italy.
IRCCS Humanitas Research Hospital, Milan, Italy.

Alexandre C Pereira (AC)

Heart Institute (InCor)/Univ São Paulo Med Sch, São Paulo, Brazil.

Manuel Romero-Gómez (M)

Digestive Diseases Unit, Virgen del Rocio University Hospital, Institute of Biomedicine of Seville, University of Seville, Seville, Spain.
Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.

Luis Bujanda (L)

Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute - Donostia University Hospital, University of the Basque Country (UPV/EHU), CIBERehd, Ikerbasque, San Sebastian, Spain.

Johannes R Hov (JR)

Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Norwegian PSC Research Center and Section of Gastroenterology, Dept Transplantation Medicine, Oslo University Hospital, Oslo, Norway.
Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.

Isabelle Migeotte (I)

Centre de Génétique Humaine, Hopital Erasme, Université Libre de Bruxelles, Brussels, Belgium.
Fonds de la Recherche Scientifique (FNRS), Brussels, Belgium.

Alessandra Renieri (A)

Genetica Medica, Azienda Ospedaliero-Universitaria Senese, Italy.
Medical Genetics, University of Siena, Italy.
Med Biotech Hub and Competence Center, Department of Medical Biotechnologies, University of Siena, Italy.

Anna M Planas (AM)

Institute for Biomedical Researhc of Barcelona (IIBB), National Spanish Research Council (CSIC), Barcelona, Spain.
Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Kerstin U Ludwig (KU)

Institute of Human Genetics, University Hospital Bonn, Medical Faculty University of Bonn, Bonn, Germany.

Maria Buti (M)

Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
Liver Unit, Department of Internal Medicine, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Universitat Autònoma de Barcelona. Departament de Medicina.Bellatera, Barcelona, Spain.

Souad Rahmouni (S)

University of Liege, GIGA-Insitute, Liege, Belgium.

Marta E Alarcón-Riquelme (ME)

GENYO. Centre for Genomics and Oncological Research: Pfizer / University of Granada / Andalusian Regional Government, Granada, Spain.
Institute for Environmental Medicine, Karolinska Institutet, 17167, Solna, Sweden.

Eva C Schulte (EC)

Institute of Virology, Technical University Munich/Helmholtz Zentrum München, Munich, Germany.
Institute of Psychiatric Phenomics and Genomics, University Hospital, LMU Munich University, Munich, Germany.
Department of Psychiatry, University Hospital, LMU Munich University, Munich, Germany.

Andre Franke (A)

Institute of Clinical Molecular Biology, Christian-Albrechts-University, Kiel, Germany.
University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.

Tom H Karlsen (TH)

Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Norwegian PSC Research Center and Section of Gastroenterology, Dept Transplantation Medicine, Oslo University Hospital, Oslo, Norway.
Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.

Luca Valenti (L)

Department of Pathopgysiology and Transplantation, Università degli Studi di Milano, Milano, Italy.
Department of Transfusion Medicine and Hematology, Precision Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.

Hugo Zeberg (H)

Department of Neuroscience, Karolinska Institutet, Sweden.
Max-Planck Institute for Evolutionary Anthropology, Leipzig, Germany.

J Brent Richards (JB)

Department of Human Genetics, McGill University, Montréal, Québec, Canada.
Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, Québec, Canada.
Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montréal, Québec, Canada.
Department of Twin Research, King's College London, London, United Kingdom.

Andrea Ganna (A)

Institute for Molecular Medicine Finland, Univerisity of Helsinki, Helsinki, Finland.
Massachusetts General Hospital, Harvard Medical School.

Classifications MeSH